ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....
Get Alerted When News Hits On This Stock - FREE!